TradingKey

关于 Evolus Inc 公司

Evolus, Inc. 是一家高性能美容公司。其主要市场是现金支付美容市场，由医疗产品组成。其候选产品包括 Jeuveau 和 Evolysse。Jeuveau 是其市售专有的 900 千道尔顿 (kDa) 纯化 A 型肉毒杆菌毒素配方，用于暂时改善成人中度至重度眉间纹（也称为皱眉纹）的外观。Jeuveau 提供 900kDa 肉毒杆菌毒素替代 BOTOX（onabotulinumtoxinA）。Jeuveau 在美国、加拿大和欧洲市场有售。Evolysse 是一系列透明质酸真皮填充剂，在监管开发中采用第一代冷技术。该系列包括多种产品，包括美国和欧洲的中面部、鼻唇沟、嘴唇和眼睛。其候选产品代表了医学美容中的两个产品类别，即可注射神经毒素和可注射真皮填充剂。

公司简介

公司代码EOLS

公司名称Evolus Inc

上市日期Feb 08, 2018

CEOMr. David Moatazedi

员工数量332

证券类型Ordinary Share

年结日Feb 08

公司地址520 Newport Center Dr Ste 1200

城市NEWPORT BEACH

上市交易所NASDAQ Global Market Consolidated

国家United States of America

邮编92660-7022

电话19492844555

网址https://www.evolus.com/

公司代码EOLS

上市日期Feb 08, 2018

CEOMr. David Moatazedi

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Vikram Malik

Independent Chairman of the Board

265.91K

+9.47%

Mrs. Brady Stewart

Independent Director

51.27K

-1.73%

Mr. David N. Gill

Independent Director

33.96K

-14.80%

Mrs. Tomoko Yamagishi-Dressler

Chief Marketing Officer

14.10K

-85.26%

Ms. Karah Parschauer, J.D.

Independent Director

--

Mr. Albert G. White, III

Independent Director

--

Mr. Nareg Sagherian

Investor Relations

--

Dr. Rui L. Avelar, M.D.

Chief Medical Officer, Head - Research and Development

--

Mr. David Moatazedi

President, Chief Executive Officer, Director

--

-100.00%

名称

名称/职务

职务

持股

持股变动

Mr. Vikram Malik

Independent Chairman of the Board

265.91K

+9.47%

Mrs. Brady Stewart

Independent Director

51.27K

-1.73%

Mr. David N. Gill

Independent Director

33.96K

-14.80%

Mrs. Tomoko Yamagishi-Dressler

Chief Marketing Officer

14.10K

-85.26%

Ms. Karah Parschauer, J.D.

Independent Director

--

Mr. Albert G. White, III

Independent Director

--

收入明细

暂无数据

暂无数据

业务

地区

暂无数据

股东统计

更新时间: 5月16日周五

持股股东

股东类型

持股股东

占比

Tang Capital Management, LLC

7.75%

Perceptive Advisors LLC

6.40%

BlackRock Institutional Trust Company, N.A.

5.93%

Nantahala Capital Management, LLC

5.66%

The Vanguard Group, Inc.

5.00%

Other

69.25%

持股股东

占比

Tang Capital Management, LLC

7.75%

Perceptive Advisors LLC

6.40%

BlackRock Institutional Trust Company, N.A.

5.93%

Nantahala Capital Management, LLC

5.66%

The Vanguard Group, Inc.

5.00%

Other

69.25%

股东类型

持股股东

占比

Hedge Fund

33.58%

Investment Advisor

26.47%

Investment Advisor/Hedge Fund

15.89%

Private Equity

6.40%

Corporation

3.31%

Individual Investor

1.95%

Research Firm

1.38%

Bank and Trust

0.60%

Pension Fund

0.60%

Other

9.82%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

360

58.30M

90.42%

-3.12M

2025Q1

367

61.71M

95.75%

-6.80M

2024Q4

349

59.00M

93.18%

-8.33M

2024Q3

345

58.57M

92.95%

-9.62M

2024Q2

337

59.72M

95.46%

-6.66M

2024Q1

324

57.99M

95.42%

-6.59M

2023Q4

309

53.87M

93.36%

-7.99M

2023Q3

309

51.63M

90.65%

-8.83M

2023Q2

309

53.08M

93.27%

-5.08M

2023Q1

308

49.88M

88.43%

-4.38M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Tang Capital Management, LLC

5.00M

7.75%

--

Mar 31, 2025

Perceptive Advisors LLC

4.13M

6.4%

-1.02M

-19.76%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

3.82M

5.93%

-13.22K

-0.34%

Mar 31, 2025

Nantahala Capital Management, LLC

3.65M

5.66%

+521.19K

+16.65%

Mar 31, 2025

The Vanguard Group, Inc.

3.22M

5%

+62.66K

+1.98%

Mar 31, 2025

Caligan Partners, LP

2.73M

4.24%

+38.77K

+1.44%

Mar 31, 2025

Medy Tox Inc

2.14M

3.31%

-1.24M

-36.82%

Dec 31, 2024

Millennium Management LLC

1.39M

2.16%

+23.61K

+1.72%

Mar 31, 2025

State Street Global Advisors (US)

1.38M

2.15%

-39.16K

-2.75%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.26M

1.96%

+47.45K

+3.91%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

SPDR S&P Pharmaceuticals ETF

0.96%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0.68%

iShares U.S. Pharmaceuticals ETF

0.23%

iShares Micro-Cap ETF

0.11%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.09%

ProShares Ultra Nasdaq Biotechnology

0.07%

Invesco Nasdaq Biotechnology ETF

0.07%

iShares Russell 2000 Growth ETF

0.03%

Proshares Ultra Russell 2000

0.02%

ProShares Hedge Replication ETF

0.02%

SPDR S&P Pharmaceuticals ETF

占比0.96%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比0.68%

iShares U.S. Pharmaceuticals ETF

占比0.23%

iShares Micro-Cap ETF

占比0.11%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.09%

ProShares Ultra Nasdaq Biotechnology

占比0.07%

Invesco Nasdaq Biotechnology ETF

占比0.07%

iShares Russell 2000 Growth ETF

占比0.03%

Proshares Ultra Russell 2000

占比0.02%

ProShares Hedge Replication ETF

占比0.02%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Evolus Inc

9.220USD

Evolus Inc

9.220

概览

公司

财务